Loew
Biotech

Ipsen inks $1.7B deal to buy Kartos for potential Jakafi add-on

Ipsen is paying $450 million upfront to buy U.S.-based Kartos Therapeutics for a phase 3-stage blood cancer drug designed to improve Jakafi treatment.
James Waldron Jun 29, 2026 8:03am
Goal disorientation and lack of vision

Evommune’s phase 2b flops, ending challenge to Novartis in hives

Jun 29, 2026 10:00am
closed close

BioCryst ends internal programs in pivot to partnerships

Jun 29, 2026 10:30am
FDA stop sign
Favicon Fierce Pharma

FDA snubs Sobi’s gout drug over manufacturing issues

Jun 29, 2026 11:04am
Glowing puzzle piece fitting into puzzle

Scancell bids for Nasdaq-listed Neuphoria to raise US profile

Jun 29, 2026 7:55am
IPO

Talawar heads to Nasdaq via SPAC deal to fund eczema bispecific

Jun 29, 2026 7:00am
More News

AstraZeneca posts phase 3 bone disease data on Strensiq heir

Jun 29, 2026 4:51am

Cash-strapped Alopexx reignites plans to go public via $30M IPO

Jun 27, 2026 8:16am

Epicrispr gene silencer enhances muscle in muscular dystrophy

Jun 26, 2026 10:40am

Fierce Biotech Layoff Tracker 2026: BioCryst, Biogen, & more

Jun 26, 2026 10:00am